Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns?-

Okabayashi, Shinji; Taku, Keisei; Hibi, Toshifumi

doi:10.23922/jarc.2019-003

Cited by 28 publications

(26 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through this system, patients with designated intractable diseases may focus on their treatment without considering treatment costs—part of a health-care system the Japanese government takes pride in globally. This system, however, causes patients to lack motivation for using biosimilars 17 , 35 , 36 given that the use of biosimilars instead of reference biologics does not decrease patient costs. Had treatment costs become cheaper, the use of biosimilars would certainly have increased due to the potential savings with no loss in benefits.…”

Section: Discussionmentioning

confidence: 99%

Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database

Matsumoto¹,

Tsuchiya

Hirano³

et al. 2021

CEOR

View full text Add to dashboard Cite

Purpose Infliximab, which was approved in 2002, had its first biosimilar launched in 2014 across Japan. However, the penetration rate of this biosimilar remains unclear given the limited data regarding its current clinical use throughout Japan. This study was conducted to describe the current clinical characteristics of patients receiving infliximab and the penetration rate of the reference infliximab and/or biosimilar infliximab using a Japanese administrative claims database. Patients and Methods This retrospective, descriptive study utilized the Japan Medical Data Vision database, a nationwide hospital-based database. Data on patients receiving infliximab recorded from April 2008 to March 2019 were extracted from the database. Patient characteristics of the reference and biosimilar infliximab groups and penetration rates according to fiscal year, target diseases diagnosis, and subsidy for intractable diseases were examined. Results A total of 9735 patients were extracted for analysis, among whom 92% (n=8950) and 8% (n=785) received only reference infliximab and its biosimilar, respectively. Both groups exhibited similar clinical characteristics. The biosimilar penetration rate increased from 0.8% in 2014 to 22.5% in 2018, with overall penetration rates throughout the period according to diagnosis (with or without subsidy) being 14.4% (with, 4.1%; without, 16.4%), 4.7% (with, 3.7%; without, 10.6%), 5.7% (with, 4.5%; without, 13.5%), and 7.5% (with, 4.4%; without, 8.2%) for rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and psoriasis, respectively. Conclusion Biosimilar infliximab is prescribed for patients with similar characteristics to reference infliximab. Despite the increasing penetration rates according to target disease, they remain much lower among patients receiving subsidy for intractable disease than among those who do not.

show abstract

Section: Discussionmentioning

confidence: 99%

Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database

Matsumoto¹,

Tsuchiya

Hirano³

et al. 2021

CEOR

View full text Add to dashboard Cite

show abstract

“…We also used two other pieces of evidence to extract the prevalence ratio and incidence rate of IBD for each region or country [8,9]. Besides, we considered the reported IBD incidence rates in nine new articles according to the literature review that was not included in the previous study [10][11][12][13][14][15][16][17][18][19]. We adjusted the geographical classi cation for incidence rates with the IHME classi cation as shown below:…”

Section: Prerequisites Datamentioning

confidence: 99%

The Emerging Epidemic of Inflammatory Bowel Disease in Asia and Iran by 2035: A Modeling Study

Olfatifar

Zali

Pourhoseingholi

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The projection studies are imperative to optimize the future need for health care systems and proper response to the public health problems such as inflammatory bowel disease (IBD). Methods: To accomplish this, we established an illness-death model based on available data to project the future prevalence of IBD in Asia regions and Iran separately from 2017 to 2035. We applied two deterministic and stochastic approaches. Results: For 2035 compared to 2020, we projected a 2.5-fold increase in prevalent cases for Iran with 69 thousand cases, a 2.3-fold increment for North Africa and the Middle East with 220 thousand cases, quadrupling of the prevalence for India with 2.2 million cases, a 1.5-fold increment for East Asia region with 4.5 million cases and a 1.6-fold increase in prevalence for High‐income Asia‐Pacific and Southeast Asia regions with 183 and 199 thousand cases respectively. Conclusions: Our results showed an emerging epidemic for the prevalence of IBD in Asia regions or/and countries. Hence, we suggest the need for emergency action to control this increasing trend in Asia and Iran.

show abstract

“…The prevalence of IBD is high in Western countries; however, the rates of IBD are also rising in many newly industrialized countries as they become more westernized. For example, the number of IBD patients has increased approximately 20-fold in the past 30 years in Japan [ 5 ]. This exponential increase suggests that environmental exposures also play critical roles in the development of IBD [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Diet–Microbiota Interactions in Inflammatory Bowel Disease

Sugihara

Kamada

2021

Nutrients

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract. Although the precise etiology of IBD is largely unknown, it is widely thought that diet contributes to the development of IBD. Diet shapes the composition of the gut microbiota, which plays critical roles in intestinal homeostasis. In contrast, intestinal inflammation induces gut dysbiosis and may affect the use of dietary nutrients by host cells and the gut microbiota. The interaction of diet and the gut microbiota is perturbed in patients with IBD. Herein, we review the current knowledge of diet and gut microbiota interaction in intestinal homeostasis. We also discuss alterations of diet and gut microbiota interaction that influence the outcome and the nutritional treatment of IBD. Understanding the complex relationships between diet and the gut microbiota provides crucial insight into the pathogenesis of IBD and advances the development of new therapeutic approaches.

show abstract

Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns?-

Cited by 28 publications

References 40 publications

Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database

Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database

The Emerging Epidemic of Inflammatory Bowel Disease in Asia and Iran by 2035: A Modeling Study

Diet–Microbiota Interactions in Inflammatory Bowel Disease

Contact Info

Product

Resources

About